Preliminary Results of a Phase 2a Clinical Trial to Evaluate Safety, Tolerability and Antiviral Activity of Intravenous Brincidofovir (BCV IV) in Immunocompromised Patients with Adenovirus Infection

Adenovirus (AdV) may cause fatal infections in immunosuppressed patients including recipients of allogeneic hematopoietic cell transplant. Brincidofovir (BCV) is a lipid conjugate of cidofovir, that crosses cell membranes and has a long intracellular half-life. The safety, tolerability and antiviral activity of intravenous BCV (BCV IV) were evaluated in a dose ascending Phase 2a ATHENA study (NCT04706923).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 106 Source Type: research